GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript
Grail Exec Says Co. In Conversations With Commercial Payers For Galleri Cancer Test
Grail Exec Expects FDA Decision On Approval For Galleri Cancer Test By Early Q1 2027; Expects Galleri Cancer Test To Be Reimbursed At $500 To $600
GRAIL Exec Expects Broad Label For Galleri Cancer Test Based On Data Co Has Submitted To FDA
Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130
GRAIL Inc (GRAL) (Q3 2026) Earnings Call Highlights: FDA Nod on the Horizon as Galleri Gains ...
Is GRAIL (GRAL) Fully Valued As Fresh Earnings Reignite Questions Over Galleri?
GRAIL (GRAL) Q3 2026 Earnings Call Transcript
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
GRAIL, Inc. Q3 2026 Earnings Call Summary
What GRAIL (GRAL) Said on Its Q3 Earnings Call
GRAIL (NASDAQ:GRAL) Slides After Q3 Revenue Miss Despite Narrower Loss
Grail tumbles as revenue misses estimates despite FDA vote
Grail Comes Up Short, Reporting Light Sales Of Its Cancer-Detecting Blood Test
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
GRAIL Reports Third Quarter 2026 Financial Results
How Long Can GRAIL Keep Burning Cash?
GRAIL to Present at the UBS Global Healthcare Conference
What GRAIL (GRAL)'s Canada Test Rollout Means For Shareholders
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.